跳至主要内容
临床试验/NCT06266104
NCT06266104Unknown不适用

Image Enhanced Endoscopy Technology to Improve the Detection of Colorectal Dysplasia in Patients With Inflammatory Bowel Disease

Royal Perth Hospital1 个研究点 分布在 1 个国家目标入组 270 人开始时间: 2024年4月3日最近更新:
适应症
干预措施

试验速览

阶段
不适用
入组人数
270
试验地点
1
主要终点
Dysplasia Detection Rate

研究概览

简要总结

Dye- spray chromoendoscopy remains the recommended gold standard approach for IBD dysplasia surveillance colonoscopy however recently published European and American guidelines recommend either dye-spray or virtual chromoendoscopy can be used for surveillance. The newer Imaged Enhanced Endoscopy technologies TXI and LCI have not formally been evaluated in IBD surveillance in a randomised controlled trial setting. These modes can easily be applied during colonoscopy and if demonstrated to be effective may save time and eliminate the need for dye-spray chromoendoscopy in the future.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
Single (Investigator)

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Patients with inflammatory bowel disease aged 18 to 75 years, that meet Australian recommendations to undergo surveillance colonoscopy will be identified and invited participate in the study.

排除标准

  • •Any active disease
  • •Inadequate bowel preparation
  • •Previous surgical resection involving the colon
  • •History of bowel cancer

研究组 & 干预措施

Dye Spray Chromoendoscopy

Placebo Comparator

Patients undergoing surveillance with dye spray chromoendoscopy

干预措施: Image Enhanced Endoscopy Filters (Procedure)

TXI

Active Comparator

Patients undergoing surveillance with TXI (Texture and Colour Enhancement Imaging)

干预措施: Image Enhanced Endoscopy Filters (Procedure)

LCI

Active Comparator

Patients undergoing surveillance with LCI (Linked Colour Imaging )

干预措施: Image Enhanced Endoscopy Filters (Procedure)

结局指标

主要结局

Dysplasia Detection Rate

时间窗: 2 years

Overall Dysplasia Detection rate

次要结局

  • Characterisation of lesions(2 years)
  • Withdrawal times(2 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Sherman Picardo

Doctor, Principal Investigator

Royal Perth Hospital

研究点 (1)

Loading locations...

相似试验